

WHO Expert Committee on Drug Dependence

N-Ethylnorpentylone

Annex 1: Member State Questionnaire

1. Overview (Q1-Q5)

Q1: Your country name.

- 86 country representatives have answered the questionnaire:

Q5: Do you have any information on the use of the **N-Ethylnorpentylone** in your country either for medical, scientific, industrial or other professional purposes, or for non-medical consumption or recreational purposes, or any other purpose?

- 24 (28%) answered yes.
- 61 (72%) answered no.

2. Section 1: Approved medical or scientific use (Q6-Q10)

Q6: Do you know if approved medical products containing **N-Ethylnorpentylone** are available in your country for human or veterinary indications?

- **“Human medical product”**
 - N=0 countries
- **“Veterinary medical product”**
 - N=0 countries
- **“Not available in medical products”**
 - N=22
- **“Do not know”**
 - N=3 countries

Q7: What are the therapeutic indications approved for **N-Ethylnorpentylone** in your country?

- All given responses expressed that there are no therapeutic indications for N-Ethylnorpentylone.

Q8: Please indicate the marketed name, dosage form(s) and strength(s) of **N-Ethylorpentylone** available in your country; also indicate the exact substance name and any special properties such as slow release, etc?

- No valid responses were given to this question.

Q9: Is **N-Ethylorpentylone** currently used in medical or scientific research (excluding use as an analytical reference standard) in your country (e.g. , is it in clinical trials for any human or veterinary indication)?

- 16 (80%) answered no, 4 (20%) answered "Do not know".

Q10: If Yes, please specify:

- No valid responses were given to this question.

3. Section 2: Non-approved medical and non-medical or non-scientific use (Q11-Q15)

Q11: Is **N-Ethylnorpentylone** used for industrial or other non-medical/non-scientific purposes in your country?

- Out of 23 responses, one indicated that **N-Ethylnorpentylone** is used for industrial or other non-medical/non-scientific purposes in their country (4%). There were eight “Do not know” responses (35%).

Q12: If Yes to question 11, please specify:

- The country representative from Norway indicated recreational use of N-Ethylnorpentylone in their country.

Q13: What is the origin/source of **N-Ethylnorpentylone** when used for legitimate non-medical/non-scientific use?

- “Imported”
 - N=1 country
- “Do not know”
 - N=7 countries

4. Section 3: Cultural, religious or ceremonial use (Q16-Q19)

Q16: Is **N-Ethylnorpentylone** used for cultural, religious or ceremonial purposes in your country?

- Out of 22 responses, 77% (N=17) indicated no cultural, religious or ceremonial use, while five country representatives answered “Do not know” (23%).

5. Section 4: Epidemiology of non-medical/non-scientific use – psychoactive purposes/recreational use (Q19-Q36)

Q19: Is **N-Ethylnorpentylone** misused for their psychoactive properties (as a recreational drug) in your country?

- Out of 23 responses, 83% (N=19) indicated misuse of N-Ethylnorpentylone.
- In one country, N-Ethylnorpentylone is reportedly not misused (4%) while three country representatives answered “Do not know” (16%).

Q20: By what route(s) of administration is **N-Ethylnorpentylone** used for non-medical/non-scientific purposes in your country?

Oral (N=8)	
Injection (N=4)	
Inhalation (N=1)	
Sniffing (N=4)	
Smoking (N=2)	
Do not know (N=10)	
Other (please specify) (N=1)	

Q21: What is the most common route of administration for **N-Ethylnorpentylone** for non-medical/non-scientific purposes?

- In six out of seven responses, oral administration was reported as the preferred intake route.

Q22: In which formulations is **N-Ethylnorpentylone** used for non-medical/non-scientific purposes in your country?

Powder (N=12)	
Tablets (N=5)	
Liquid or solution for oral	

administration/use (N=0)	
Solution for injection (N=0)	
Other (please specify) (N=10)	

Q23: What is (are) the source(s) of **N-Ethylnorpentylone** for non-medical/non-scientific use in your country?

Legal manufacturing (N=0)	
Legal trade (N=0)	
Illegal manufacturing (N=2)	
Diversion (from legal supply chain)	
Smuggling (from other countries) (N=11)	
Do not know (N=4)	
Other (please specify) (N=2)	

Q24: Are there any specific subpopulations in your country known to misuse **N-Ethylnorpentylone**?

- In three out of 16 responding countries (19%), there are specific subpopulations misusing N-Ethylnorpentylone. In the remaining 13 countries specific subpopulations are not known to misuse N-Ethylnorpentylone.

Q27: As an expert, what negative health impact do you believe the non-medical consumption of **N-Ethylnorpentylone** has in your country?

- Out of 17 responses, a total of six country representatives evaluated the negative health impact of N-Ethylnorpentylone as either “serious” (18%) or “substantial” (18%). In five countries, N-Ethylnorpentylone were found to have a “negligible” negative health impact (29%). Four country representatives answered “Do not know” (35%).

Q29: Are you aware of any emergency room/department visits related to the use of **N-Ethylorpropylone** in your country?

- Out of 17 responses, six country representatives (35%) were aware of any emergency room/department visits related to the use of N-Ethylorpropylone. The remaining eleven responses (65%) were unaware of such visits.

Q34: Are you aware of people presenting for drug dependence treatment due to the use of **N-Ethylorpropylone** in your country?

- Out of 16 responses, two country representatives (13%) were aware of people presenting for drug dependence treatment due to the use of N-Ethylorpropylone. The majority answered “No” (50%) or “Do not know” (38%).

6. Section 5: Current Control (Q37-Q48)

Q37: Is **N-Ethylnorpentylone** currently controlled under national legislation in order to regulate its availability in your country?

- Out of 23 responses, the majority of countries have a national control legislation in place (78%). In two countries (9%), no national legislation exists and three country representatives answered “Do not know” (11%).

Q39: What is the scope of this control?

Production	N=14	
Manufacture	N=16	
Export	N=15	
Import	N=16	
Distribution	N=16	
Use	N=11	
Possession	N=16	
Do not know	N=0	
Other (please specify)	N=3	

Q40: Is the current control a temporary provision in your country?

- Out of 18 responding countries, the current control is a temporary provision in one country.

Q42: Have there been challenges to implementing controls of **N-Ethylnorpentylone** in your country?

- Out of 17 responding countries, no challenges in implementing controls were reported. One country representative answered “Do not know” (6%). In the remaining countries, no challenges in implementing controls were reported (94%).

Q46: If **N-Ethylorpentylone** was to be placed under international control, will your country have the capacity to enforce the control at the national level?

- Out of 23 responses, 22 reported sufficient capacities (96%; Australia, Brazil, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Jordan, Lithuania, New Zealand, Norway, Poland, Portugal, Qatar, Russian Federation, Serbia, Singapore, Spain, Sweden, United States of America). One country representative answered “Do not know” (4%; The Netherlands).

Q47: If **N-Ethylorpentylone** was to be placed under international control, does your country have the forensic laboratory capacity to analyse the substance (identification, purity)?

- Out of 23 responses, 21 reported sufficient capacities (91%; Australia, Brazil, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Lithuania, New Zealand, Norway, Poland, Portugal, Qatar, Russian Federation, Serbia, Singapore, Spain, Sweden, United States of America). Two country representatives answered “Do not know” (9%; Jordan, Netherlands).

7. Conclusions

This survey was taken by country representatives from all WHO regions but data on N-Ethylnorpentylone could be provided by only 1 in 4 countries. In countries with available data on N-Ethylnorpentylone, use is not approved in any country, however, abuse or recreational use has been reported in nearly all countries.

Data on user populations, route of administration, as well as adverse effects of N-Ethylnorpentylone are relatively scarce and provided only by a fraction of respondents. The limited data suggest that N-Ethylnorpentylone is commonly obtained illegally by smuggling from other countries or via internet sales. The substance is often taken orally as powder or tablets but characteristics of user populations remain largely unknown.

A similar number of countries judged the extent of public health problems related to N-Ethylnorpentylone to be substantial/serious or negligible. Adverse effects attributable to N-Ethylnorpentylone have been characterized based on case studies and range from tachycardia and hypertension to cardiac arrest to respiratory failure. Systematic data on N-Ethylnorpentylone related admissions to emergency rooms or addiction facilities are lacking. Further, unambiguous determination of the substance has been cited a problem with regard to forensic examination of deceased bodies, which could lead to underreporting of deaths. It should also be stressed that other psychoactive substances with similar chemical structure and properties exist (e.g. N-Ethylhexedrone), which could be easily confused with N-Ethylnorpentylone by both drug users as well as police or medical personnel.

The majority of illegal activities related to N-Ethylnorpentylone have been located at internet sales. Seizures of the substance have been reported by twelve countries, with amounts ranging from a few grams to several kilograms. In the vast majority of countries with data on N-Ethylnorpentylone, respondents indicate that the substance is already under control without any challenges in implementing control measures. Nearly all countries indicated sufficient capacities in case N-Ethylnorpentylone was placed under international control.